Brief: Mesoblast Says Raises A$260 Million For Ryoncil Commercial Launch
14/01/2025 01:25
Jan 14 (Reuters) - Mesoblast MSB.AX :
* RAISES A$260 MILLION FOR RYONCIL COMMERCIAL LAUNCH
* PLACEMENT AT A$2.50 PER SHARE
Further company coverage: MSB.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mesoblast
See all newsBrief: Mesoblast William Burns To Retire From Board At 2026 AGM
Brief: Mesoblast Says Q1 Net Revenues Up 44%
Australia's Mesoblast hits one-month high on upbeat quarterly update
Australia's Mesoblast drops as Bell Potter cuts target price after key drug misses sales view
Brief: Mesoblast Says FDA Approves New Potency Assay For Commercial Ryoncil